With many cell and gene therapies skipping phase III trials entirely, academics must get to grips with GMP early.

Cell and gene therapies have earned a high profile in recent years, but the field’s rate of growth has led to a gold rush on talent.

What if research hospitals could fully develop and process cell and gene therapies themselves?

Miguel Forte argues it’s time to fine tune the way we target solid tumors...

The gene therapy sector is booming, but can the industry address all the teething problems?

The cell and gene therapy industry has amazing statistics. But to reach the next level, the industry must address its talent gap.

How an understanding of the regulatory framework is essential for the future generations of cell and gene therapy professionals.

Contract laboratories need to be treated as equal partners rather than service providers.

Cell and gene therapies require the very highest levels of quality, so an effective fill-finish solution is essential to manufacturing operations.

The Pistoia Alliance have announced their plans to develop a toolkit to help companies navigate large datasets.